Allopurinol does not affect the anticonvulsant activity of carbamazepine and valproate in maximal electroshock-induced convulsions in mice

Polish Journal of Pharmacology

Volumn 56, Issue 1, 2004, Pages 67-72

  Parada Turska, Jolanta ^a   Czuczwar, Mirosław ^a   Kiś, Jacek ^a   Czuczwar, Piotr ^a   Cioczek, Anna ^a   Łuszczki, Jarogniew ^a   Czuczwar, Stanisław J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Allopurinol; Carbamazepine; Mice; Seizures; Valproate

Indexed keywords

ALLOPURINOL; CARBAMAZEPINE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CONVULSION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; ELECTRIC SHOCK; EPILEPSY; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; SEIZURE THRESHOLD;

ALLOPURINOL; ANIMALS; ANTICONVULSANTS; BODY WEIGHT; CARBAMAZEPINE; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; ELECTROSHOCK; INJECTIONS, INTRAPERITONEAL; MALE; MICE; POLAND; SEIZURES; TIME FACTORS; VALPROIC ACID; XANTHINE OXIDASE;

EID: 1942421130     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Blair B, Fabrizio M: Pharmacology for renal calculi. Expert Opin Pharmacother, 2000, 1, 435-441.
2. Boissier JR, Tardy J, Diverres JC: Une nouvelle méthode simple pour explorer l'action «tranquillisante»: le test do la cheminée, Med Exp (Basel), 1960, 3, 81-84.
3. Borges F, Fernandes E, Roleira F: Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem, 2002, 9, 195-217.
4. Coppola G, Pascotto A: Double-blind, placebo-controlled, cross-over trial of allopurinol as add-on therapy in childhood reftactory epilepsy. Brain Dev, 1996, 18, 50-52.
5. Czuczwar SJ, Borowicz KB: Polytherapy in epilepsy: the experimental evidence. Epilepsy Res, 2002, 52, 15-23.
6. Guzeva VI, Gusel VA, Mikhailov IB: Allopurinol in the combined therapy of severe forms of epilepsy in children. Zh Nevropatol Psikhiatr, 1988, 88, 69-72.
7. Hoppe SA, Terrell DJ, Gottlieb SF: The effect of allopurinol on oxygen-induced seizures in mice. Aviat Space Environ Med, 1984, 55, 927-930.
8. Klandorf H, Rathore DS, Iqbal M, Shi X, Van Dyke K: Accelerated tissue aging and increased oxidative stress in broiler chickens fed allopurinol. Comp Biochem Physiol PTC, 2001, 129, 93-104.
9. Litchfield JT, Wilcoxon F A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther, 1949, 96, 99-113.
10. Lóscher W, Schmidt D: Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res, 1988, 2, 145-181.
11. Mikhailov IB, Gusel VA: Pharmacodynamic mechanisms for reducing the activity of an epileptogenic focus with allopurinol. Zh Nevropatol Psikhiatr, 1983, 83, 870-873.
12. Murashima YL, Kasamo K, Suzuki J: Antiepileptic effects of allopurinol on EL mice are associated with changes in SOD isoenzyme activities. Epilepsy Res, 1998, 32, 254-265.
13. Ogiso T, Ito Y, Iwaki M, Tsunekawa K: Drug interaction between phenytoin and allopurinol. J Pharmacobiodyn, 1990, 13, 36-43.
14. Pittman JR, Bross MH: Diagnosis and management of gout. Am Fam Physician, 1999, 59, 1799-1806.
15. Sander JW, Patsalos PN: Allopurinol as an add-on drug in the management of intractable epilepsy. Epilepsy Res, 1988, 2, 223-225.
16. Tada H, Morooka K, Arimoto K, Matsuo T: Clinical effects of allopurinol on intractable epilepsy. Epilepsia, 1991, 32, 279-283.
17. Wada Y, Hasegawa H, Nakamura M, Yamaguchi N: Anticonvulsant effect of allopurinol on hippocampal-kindled seizures. Pharmacol Biochem Behav, 1992, 42, 899-901.
18. Zagnoni PG, Bianchi A, Zolo P, Canger F, Cornaggia C, D'Alessandro P, DeMarco P et al.: Allopurinol as add-on therapy in refractory epilepsy: a double-blind placebo-controlled randomized study. Epilepsia, 1994, 35, 107-112.